Ghrelin Receptor Agonist Hexarelin Reduces Morphine Tolerance in Rats

Opioid analgesics like morphine are highly effective for severe pain, but their long-term use is often limited by the development of antinociceptive tolerance, where higher doses are required to achieve the same pain relief. This tolerance can lead to increased dosing, greater side effects, and a higher risk of opioid dependence. While the mechanisms underlying opioid tolerance are complex, involving neuronal adaptations and receptor desensitization, the specific role of the ghrelin receptor system in modulating this process has been largely unexplored.

The study found that rats treated with morphine alone developed significant antinociceptive tolerance, evidenced by a 65% reduction in tail-flick latency by day 14 compared to their initial baseline (p<0.001). In contrast, the co-administration of hexarelin significantly attenuated this tolerance. The hexarelin-treated group maintained a 55% higher tail-flick latency on day 14 compared to the morphine-alone group (p<0.001), indicating sustained analgesic efficacy. The most striking finding was that co-administration of hexarelin reduced the development of morphine antinociceptive tolerance by over 50% compared to the morphine-alone group, maintaining analgesic efficacy throughout the 14-day treatment period. Furthermore, the cumulative dose of morphine required to maintain a consistent analgesic effect was reduced by 48% in the hexarelin co-treated group over 7 days compared to the morphine-alone group (p<0.01).